Screening and monitoring for bladder cancer: Refining the use of NMP22

Journal of Urology

Volumn 166, Issue 1, 2001, Pages 75-78

  Ponsky, Lee E ^a   Sharma, Shashikala ^a   Pandrangi, Lakshmi ^a   Kedia, Sumita ^a   Nelson, David ^a   Agarwal, Ashok ^a   Zippe, Craig D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antigens; Biological; Bladder neoplasms; Carcinoma; Neoplasm; Nuclear matrix; Transitional cell; Tumor markers

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CARCINOMA; CANCER SCREENING; CELL NUCLEUS MATRIX; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; RELIABILITY; TRANSITIONAL CELL CARCINOMA;

EID: 0034967612     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66080-6     Document Type: Article

References (21)

1. Cancer statistics, 1999
2. Predicting cancer progression in patients with stage T1 bladder carcinoma
3. Multivariate analysis of progression in superficial bladder cancer
4. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder
5. Survival rate of bladder tumors: An analysis of 2304 patients with bladder tumors in the Tokai Urological Cancer Registry
6. Detection of bladder cancer recurrence by microsatellite analysis of urine
7. Molecular detection of primary bladder cancer by microsatellite analysis
8. Comparison of screening methods in the detection of bladder cancer
9. Immunocyt: A new tool for detecting transitional cell cancer of the urinary tract
10. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
11. Bladder cancer-associated nuclear matrix proteins
12. Improved detection of recurrent bladder cancer using the Bard BTA stat test
13. Editorial: Do we have a prostate specific antigen for bladder cancer?
14. Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer-screening for urothelial cancer in patients with microscopic hematuria
15. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat
16. Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer
17. Urinary nuclear matrix protein 22 (NMP22) as a marker for screening urothelial cancer in patients with microscopic hematuria
18. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer
19. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder
20. Prospective, multi-center study of NMP22 and cytology in patients with hematuria
21. Use of a new tumor marker, urinary NMP22 in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment